Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Alnylam Pharmaceuticals HELIOS-B Phase 3 Study Of AMVUTTRA Shows Vutrisiran Improved Cardiac Structure And Function In ATTR-CM Patients With Amyloid Regression And Preserved Kidney Function

Author: Benzinga Newsdesk | November 10, 2025 03:58am

− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran's Differentiated Profile –
− Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac Parameters –
– In a Cohort of HELIOS-B Patients, CMR Imaging Showed Amyloid Regression in 22% of Vutrisiran Treated Patients with No Regression Found in Patients Who Received Placebo –
– Treatment with Vutrisiran Preserved Kidney Function in HELIOS-B Patients, and Reduced Risk of Death and Cardiovascular Events in Patients with Advanced Chronic Kidney Disease –

Posted In: ALNY